IP Library › Granted Patent US 12,510,550
Granted Patent B2
US 12,510,550 · App. 18/227,421 · Granted Dec 30, 2025

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof

Inventor: Stuart Field (Boulder, CO)
Assignee: SomaLogic Operating Co., Inc.
G01N33/6893G01N2800/085G01N2800/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,510,550
App. No.
18/227,421
Granted
Dec 30, 2025
Kind
B2
Abstract

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD), and more specifically one or more of the following associated conditions of steatosis, lobular inflammation, hepatocyte ballooning and fibrosis, are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided.

Claims (21)

1 . A method of determining a score for a subject by detecting protein levels of a set of biomarker proteins in a sample from a subject, comprising: (a) contacting a sample from a subject with a set of capture reagents, wherein one capture reagent specifically binds integrin, alpha 1/beta 1 (ITGA1/ITGB1), wherein one capture reagent specifically binds heat shock protein 90 kDa alpha/beta (HSP90AA1/HSP90AB1), wherein one capture reagent specifically binds aromatic L-amino-acid decarboxylase (DDC), and wherein each other capture reagent specifically binds to one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen different proteins selected from aminoacylase 1 (ACY1), Complement component 7 (C7), collectin (COLEC11), colony stimulating factor 1 receptor (CSF1R), decorin (DCN), kynureninase (KYNU), P450 cytochrome oxidoreductase (POR), low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B), galectin-3-binding protein (LGALS3BP), antithrombin-III (SERPINC1), Insulin-like growth factor-binding protein 7 (IGFBP7), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform/phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3CA/PIK3R1), N-acetyl-D-glucosamine kinase (NAGK), thyroxine-binding globulin (SERPINA7), and thrombospondin 2 (THBS2), and (b) detecting the amount of each capture reagent conjugated to the protein to which it specifically binds, thereby detecting one capture reagent that specifically binds ITGA1/ITGB1, one capture reagent that specifically binds HSP90AA1/HSP90AB1, and one capture reagent that specifically binds DDC, and detecting the one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen capture reagents that specifically bind to the different biomarker proteins selected from ACY1, C7, COLEC11, CSFIR, DCN, KYNU, POR, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, SERPINA7, and THBS2, thereby detecting protein levels of a set of biomarker proteins in the sample from the subject and (c) determining a score in a statistical model based on input of the levels of the set of biomarkers measured;

wherein each capture reagent is an antibody or an aptamer.

2 . The method of claim 1 , wherein one capture reagent specifically binds ITGA1/ITGB1, one capture reagent specifically binds HSP90AA1/HSP90AB1, and one capture reagent specifically binds DDC, and at least one of the other capture reagents specifically binds to ACY1 or FCGR3B.

3 . The method of claim 1 , wherein the set of capture reagents further comprises at least one additional capture reagent that specifically binds to a biomarker protein selected from THBS2, COLEC11, CSFIR, KYNU, and POR.

4 . The method of claim 1 , wherein the set of capture reagents comprises capture reagents that specifically bind to a different biomarker protein comprising ACY1, THBS2, COLEC11, CSFIR, KYNU, FCGR3B, and POR.

5 . The method of claim 1 , wherein at least one of the capture reagents specifically binds to C7 or COLEC11.

6 . The method of claim 1 , wherein the set of capture reagents comprises at least three capture reagents, wherein one capture reagent specifically binds ITGA1/ITGB1, one capture reagent specifically binds HSP90AA1/HSP90AB1, and one capture reagent specifically binds DDC, and each other capture reagent of the set of capture reagents specifically binds to a different biomarker protein selected from C7, COLEC11, THBS2, ACY1, CSFIR, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN.

7 . The method of claim 1 , wherein the set of capture reagents comprises at least four capture reagents, wherein one capture reagent specifically binds ITGA1/ITGB1, one capture reagent specifically binds HSP90AA1/HSP90AB1, and one capture reagent specifically binds DDC, and each other capture reagent of the set of capture reagents specifically binds to a different biomarker protein selected from C7, COLEC11, THBS2, ACY1, CSFIR, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, SERPINA7, and DCN.

8 . The method of claim 1 , wherein two capture regents specifically bind C7 and COLEC11.

9 . The method of claim 8 , wherein the set of capture reagents comprises capture reagents that specifically bind to a different biomarker protein comprising C7, COLEC11, THBS2, ITGA1/ITGB1, HSP90AA1/HSP90AB1, ACY1, CSFIR, KYNU, POR, IGFBP7, PIK3CA/PIK3R1, NAGK, DDC, SERPINA7, and DCN.

10 . The method of claim 1 , wherein each capture reagent is an aptamer.

11 . The method of claim 10 , wherein at least one aptamer is a slow off-rate aptamer.

12 . The method of claim 11 , wherein at least one slow off-rate aptamer comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 nucleotides with modifications.

13 . The method of claim 10 , wherein each slow off-rate aptamer binds to its target protein with an off rate (t 1/2 ) of ≥30 minutes, ≥60 minutes, ≥90 minutes, ≥120 minutes, ≥150 minutes, ≥180 minutes, ≥210 minutes, or ≥240 minutes.

14 . The method of claim 1 , wherein the sample is selected from a blood sample, a serum sample, and a plasma sample.

15 . A method of determining a score for a subject by detecting protein levels of a set of biomarkers in a sample from a subject, comprising (a) contacting a sample from a subject with a set of capture reagents, wherein one capture reagent specifically binds ITGA1/IGTB1, one capture reagent specifically binds POR, one capture reagent specifically binds HSP90AA1/HSP90AB1, one capture reagent specifically binds DDC, and wherein each other capture reagent specifically binds to a different protein selected from ACY1, C7, COLEC11, CSFIR, DCN, KYNU, FCGR3B, LGALS3BP, SERPINC1, IGFBP7, PIK3CA/PIK3R1, NAGK, SERPINA7, and THBS2, (b) detecting the amount of each capture reagent conjugated to the protein to which it specifically binds, thereby detecting protein levels of a set of biomarkers in the sample from the subject and (c) determining a score in a statistical model based on input of the levels of the set of biomarkers measured;

wherein each capture reagent is an antibody or an aptamer.

16 . A method of determining a score for a subject by detecting protein levels in a sample from a subject, comprising (a) contacting a sample from a subject with a set of capture reagents, wherein one capture reagent specifically binds FCGR3B, one capture reagent specifically binds ACY1, one capture reagent specifically binds KYNU, and wherein each other capture reagent specifically binds to a different protein selected from COLEC11, CSFIR, ITGA1/ITGB1, POR, and THBS2, (b) detecting the level of each capture reagent conjugated to the protein to which it specifically binds, thereby detecting one capture reagent that specifically binds FCGR3B, one capture reagent that specifically binds ACY1, one capture reagent specifically binds KYNU, and at least one, at least two, at least three, at least four, at least five, or at least six capture reagents that specifically bind to the proteins selected from COLEC11, CSFIR, ITGA1/ITGB1, POR, and THBS2, in the sample from the subject, and determining whether a level of at least one biomarker protein selected from ACY1, COLEC11, CSFIR, ITGA1/ITGB1, KYNU, POR, FCGR3B, and THBS2 is higher than a control level of the respective biomarker protein, and (c) determining a score in a statistical model based on input of the levels of the set of biomarkers measured;

wherein each capture reagent is an antibody or an aptamer.

17 . The method of claim 1 , wherein the statistical model comprises a naïve Bayes model.

18 . The method of claim 16 , wherein the set of capture reagents comprises at least three capture reagents or at least four capture reagents or at least five capture reagents, wherein one capture reagent specifically binds FCGR3B, one capture reagent specifically binds ACY1, one capture reagent specifically binds KYNU, and each other capture reagent of the set of capture reagents specifically binds to a different biomarker protein selected from THBS2, COLEC11, CSFIR, KYNU, ITGA1/ITGB1, and POR.

Continuity (4)
Continuation 16074181
Provisional Application 62362019 · Jul 13, 2016
Provisional Application 62292582 · Feb 8, 2016
Related Publication 20240094222A1 · Mar 21, 2024
References Cited (95)
US 5475096A · Gold et al. · 1995 [cited by applicant]
US 5580737A · Polisky et al. · 1996 [cited by applicant]
US 5660985A · Pieken et al. · 1997 [cited by applicant]
US 5705337A · Gold et al. · 1998 [cited by applicant]
US 5763177A · Gold et al. · 1998 [cited by applicant]
US 6001577A · Gold et al. · 1999 [cited by applicant]
US 6242246B1 · Gold et al. · 2001 [cited by applicant]
US 6291184B1 · Gold et al. · 2001 [cited by applicant]
US 6458539B1 · Gold et al. · 2002 [cited by applicant]
US 6458543B1 · Gold et al. · 2002 [cited by applicant]
US 6503715B1 · Gold et al. · 2003 [cited by applicant]
US 6544776B1 · Gold et al. · 2003 [cited by applicant]
US 8232065B2 · Urdea et al. · 2012 [cited by applicant]
US 8357497B2 · Urdea et al. · 2013 [cited by applicant]
US 9103837B2 · Nikrad et al. · 2015 [cited by applicant]
US 9423403B2 · Nikrad et al. · 2016 [cited by applicant]
US 9612248B2 · Nikrad et al. · 2017 [cited by applicant]
US 9945875B2 · Nikrad et al. · 2018 [cited by applicant]
US 10359435B2 · Nikrad et al. · 2019 [cited by applicant]
US 20080311593A1 · Younossi et al. · 2008 [cited by applicant]
US 20090004667A1 · Zichi et al. · 2009 [cited by applicant]
US 20090098549A1 · Schneider et al. · 2009 [cited by applicant]
US 20110152115A1 · Staudt et al. · 2011 [cited by applicant]
US 20120040861A1 · Williams · 2012 [cited by examiner]
US 20120077695A1 · Ostroff et al. · 2012 [cited by applicant]
US 20120101002A1 · Riel-Mehan et al. · 2012 [cited by applicant]
US 20130085079A1 · Gill et al. · 2013 [cited by applicant]
US 20140135302A1 · Nikrad et al. · 2014 [cited by applicant]
US 20140228233A1 · Pawlowski et al. · 2014 [cited by applicant]
US 20140303018A1 · Nikrad et al. · 2014 [cited by applicant]
US 20150232837A1 · Thibonnier · 2015 [cited by applicant]
US 20160154005A1 · Paramithiotis · 2016 [cited by examiner]
US 20160258856A1 · Kim et al. · 2016 [cited by applicant]
US 20170227550A1 · Nikrad · 2017 [cited by examiner]
US 20170335395A1 · Chen-Plotkin et al. · 2017 [cited by applicant]
US 20180016638A1 · Horan et al. · 2018 [cited by applicant]
US 20180100197A1 · Knudsen · 2018 [cited by applicant]
US 20180135019A1 · Zannettino et al. · 2018 [cited by applicant]
KR 20130087585A · 2013 [cited by applicant]
WO 2010000835A1 · 2010 [cited by applicant]
WO 2012069511A1 · 2012 [cited by applicant]
WO WO2014043421A1 · 2014 [cited by examiner]
WO 2014150198A2 · 2014 [cited by applicant]
WO 2014150198A3 · 2014 [cited by applicant]
WO 2016196945A1 · 2016 [cited by applicant]
WO 2016205723A2 · 2016 [cited by applicant]
WO 2017139254A1 · 2017 [cited by applicant]
WO 2019018610A1 · 2019 [cited by applicant]
WO 2020018461A1 · 2020 [cited by applicant]
Tsutsui (J. Clin. Gastroenterol. 2010 44:440). (Year: 2010). [cited by examiner]
Joshi (I) (J. Biol. Chem. 2011 286:24581) (Year: 2011). [cited by examiner]
Joshi (II)(Virology 2013 436:162). (Year: 2013). [cited by examiner]
2011. [cited by examiner]
2010. [cited by examiner]
Ke et al., “Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma,” J. Transl. Med. 17(1):140, pp. 1-10 (2019). [cited by applicant]
Beljaar, L., et al. WNT-5A regulates TGF—related activities in liver fibrosis, Am J Physiol Gastrointest Liver Physiol 312:G219-G227 (2017). [cited by applicant]
Coulon, S. et al. Role of Vascular Endothelial Growth Factor in the Pathophysiology of Nonalcoholic Steatohepatitis in Two Rodent Models, Hepatology, 57(5):1793-1805 (2013). [cited by applicant]
Takeshita et al., “The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial”, Diabetologia 57(5):878-890 (2014). [cited by applicant]
Umenura, T. et al. Lack of association between FCRL3 and FcyRII polymorphisms in Japanese type 1 autoimmune hepatitis, Clinical Immunology 122:338-342 (2007). [cited by applicant]
Xu et al., “Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alterations in gene expression in the aorta and liver”, Atherosclerosis 206(2):427-433 (200… [cited by applicant]
Atay et al., “Morphologic and proteomic characterization of exosomes released by cultured extravillous trophoblast cells,” Experiemental Cell Research 317:1192 (2011). [cited by applicant]
Bell et al., “Serum proteomics and biomarker discovery across the sprectrum of nonalcoholic fatty liver disease,” Hepatology, 51(1):111-120, Jan. 2010. [cited by applicant]
Brunt et al., “Pathology of fatty liver disease,” 2007, Modern Pathol., 20: S40-S48. [cited by applicant]
Campbell et al., “Monoclonal Antibody Technology,” Elsevier Science Pub, 15 pages (1984). [cited by applicant]
Gold et al., “Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery,” 2010, PLoS One 5(12):e15004. [cited by applicant]
Gronthos et al., “Heat Shock Protein-90 beta is Expressed at the Surface of Multipotential Mesenchymal Precursor Cells: Generation of a Novel Monoclonal Antibody, STRO-4, with Specificity for Mesenchymal Precursor Cells… [cited by applicant]
Hua X, et al., “Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients,” Clin Endocrinol (Oxf). Jun. 2014;80(6):877-83. Epub Dec. 5, 2013. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2021/017217, mailed Jul. 26, 2021, 18 pages. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US2017/016798, dated May 19, 2017, 19 pages. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for PCT/US2014/022547 date of mailing of Oct. 17, 2014. [cited by applicant]
Invitation to pay additional fees from the International Searching Authority for international application No. PCT/US2014/022547, date of mailing of Jul. 8, 2014. [cited by applicant]
Kleiner et al., “Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease,” Hepatology, 41(6):1312-1321, Jun. 2005. [cited by applicant]
Kraemer et al., “From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay,” PLoS One 6(10): e26332, year 2011. [cited by applicant]
Moylan et al., “Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease,” Hepatology, 59(2):471-482, Dec. 13, 2013. [cited by applicant]
Musso G, et al, “Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity,” Ann Med. Dec. 2011;43(8):617-49. Epub Nov. 2, 2010. [cited by applicant]
Nejjari et al., “Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C”, J. Pathol. 195(4):473-481 (2001). [cited by applicant]
Nikrad MP, et al., “Novel serum protein signature associated with non-alcoholic fatty liver disease,” 2013. [cited by applicant]
Nishikawa et al., “Impaired Metabolic Compensation in Adipose Tissues and Functional Alignment by Complemented Stem Cells in Mice with Progressive Nonalcoholic Fatty Liver Disease,” 2014, 60(4):735A. [cited by applicant]
Palaniyar (J. Immunology 2005 vol. 174, p. 7325) 2005. [cited by applicant]
Pearce et al., “Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD,” Biomarker Research 2013, 1:7, pp. 1-11. [cited by applicant]
Polyzos SA, et al. “Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease,” Hormones (Athens). Jul.-Sep. 2013;12(3):405-16. [cited by applicant]
Sanyal et al., “Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis,” 2010, NEJM, 362: 1675-1685. [cited by applicant]
Selman L, Hansen S. “Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1),” Immunobiology. Sep. 2012;217(9):851-63. Epub Feb. 4, 2012. [cited by applicant]
Sharma et al., “Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2),” Cellular and Molecular Gastroenterology and Hepatology 5 (3… [cited by applicant]
Shin et al., “Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes,” Diabetes Res Clin Pract. Oct. 2011;94(1):156-62. Epub Sep. 8, 2… [cited by applicant]
Tascilar et al., “Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer,” Annals of Oncology, 10 Suppl. 4:S107-S110, 1999. [cited by applicant]
Tian et al., “Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men,” Obes Rev. Apr. 2012;13(4):381-7. Epub Jan. 12, 2012. [cited by applicant]
Tockman, “Considerations in Bringing a Cancer Biomarker to Clinical Application,” Cancer Research (Suppl.), 52:2711s-2718s, 1992. [cited by applicant]
Tokushige et al., “Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease,” Journal of Gastroenterology, 48(12):1392-1400, Mar. 13, 2013. [cited by applicant]
Tsutsui et al., “Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately than Serum Alanine Amino Transferase Levels,” J Clin Gastroenterol, 2010,… [cited by applicant]
Vali et al., “Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study,” Lancet Gastroenterol Hepatol 8: 714-25… [cited by applicant]
Varchetta et al., “Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection,” Gut, Dec. 16, 2015, Abstract only. [cited by applicant]
Williams et al., “Integrin [alpha]1-null Mice Exhibit Improved Fatty Liver When Fed a High Fat Diet Despite Severe Hepatic Insulin Resistance”, J. Biol. Chem., 290(10):6546-6557 (2015). [cited by applicant]
Wruck et al., “Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes,” Scientific Data, vol. 2, Dec. 8, 2015, pp. 1-10. [cited by applicant]
Y. Yilmaz, “Review Article: is Non-alcoholic Fatty Liver Disease a Spectrum, or are Steatosis and Non-alcoholic Steatohepatitis Distinct Conditions?” Alimentary Pharmacol. Ther., 2012; 36(9):815-823. [cited by applicant]